Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets Execution Current Convertible Debenture Maturity Extended; Further Debt Optimization Planned VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel cancer therapies, today pr ...